Chemical Compound Review:
Talnetant 3-hydroxy-2-phenyl-N-(1...
Synonyms:
SureCN74221, CHEMBL275544, CHEBI:106596, CID133090, DCL000241, ...
Foley,
Sanger,
Altamura,
Sanger,
Potts,
Quartara,
Schmidt,
Medhurst,
Toulouse,
Brawner,
Lee A. Dawson,
Katherine J. Cato,
Claire Scott,
Jeannette M. Watson,
Martyn D. Wood,
Richard Foxton,
Raúl de la Flor,
Gareth A. Jones,
James Nc Kew,
Jane E. Cluderay,
Eric Southam,
Graham S. Murkitt,
Jane Gartlon,
Darrel J. Pemberton,
Declan Nc Jones,
Ceri H. Davies,
Jim Hagan,
Martin,
Griswold,
Hay,
Giardina,
Gaultier,
Sarau,
Fioramonti,
Bueno,
Webb,
Elshourbagy,
- Neurokinin NK1 and NK3 receptors as targets for drugs to treat gastrointestinal motility disorders and pain. Sanger, G.J. Br. J. Pharmacol. (2004)
- In vitro and in vivo characterization of NK3 receptors in the rabbit eye by use of selective non-peptide NK3 receptor antagonists. Medhurst, A.D., Hay, D.W., Parsons, A.A., Martin, L.D., Griswold, D.E. Br. J. Pharmacol. (1997)
- Intestinal anti-nociceptive behaviour of NK3 receptor antagonism in conscious rats: evidence to support a peripheral mechanism of action. Fioramonti, J., Gaultier, E., Toulouse, M., Sanger, G.J., Bueno, L. Neurogastroenterol. Motil. (2003)
- Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 2. Identification of (S)-N-(1-phenylpropyl)-3-hydroxy-2-phenylquinoline-4-carboxamide (SB 223412). Giardina, G.A., Raveglia, L.F., Grugni, M., Sarau, H.M., Farina, C., Medhurst, A.D., Graziani, D., Schmidt, D.B., Rigolio, R., Luttmann, M., Cavagnera, S., Foley, J.J., Vecchietti, V., Hay, D.W. J. Med. Chem. (1999)
- Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonist. Sarau, H.M., Griswold, D.E., Potts, W., Foley, J.J., Schmidt, D.B., Webb, E.F., Martin, L.D., Brawner, M.E., Elshourbagy, N.A., Medhurst, A.D., Giardina, G.A., Hay, D.W. J. Pharmacol. Exp. Ther. (1997)
- Tachykinin receptors antagonists: from research to clinic. Quartara, L., Altamura, M. Current drug targets. (2006)
- Modulation of peristalsis by NK(3) receptor antagonism in guinea-pig isolated ileum is revealed as intraluminal pressure is raised. Sanger, G.J., Tuladhar, B.R., Brown, J., Aziz, E., Sivakumar, D., Furness, J.B. Autonomic & autacoid pharmacology (2007)
- In vitro and in vivo characterization of the non-peptide NK3 receptor antagonist SB-223412 (talnetant): potential therapeutic utility in the treatment of schizophrenia. Dawson, L.A., Cato, K.J., Scott, C., Watson, J.M., Wood, M.D., Foxton, R., de la Flor, R., Jones, G.A., Kew, J.N., Cluderay, J.E., Southam, E., Murkitt, G.S., Gartlon, J., Pemberton, D.J., Jones, D.N., Davies, C.H., Hagan, J. Neuropsychopharmacology (2008)
- Lithiation of functionalized fluoroquinolines: synthesis of dihalo-2-phenylquinoline-4-carboxamides and in vitro evaluation as NK-3 receptor ligands for medical imaging studies. Bennacef, I., Tymciu, S., Dhilly, M., Mongin, F., Quéguiner, G., Lasne, M.C., Barré, L., Perrio, C. J. Org. Chem. (2004)